Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.54 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.42 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.36 |
| ▸ | IGF1R | P08069 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13667217 | 1.00 | HRH4 (0.54) | HRH4PRKD1PRKD2KCNH2HRH3 | |
| SCHEMBL13668487 | 1.00 | HRH4 (0.54) | HRH4PRKD1PRKD2KCNH2HRH3 | |
| SCHEMBL14693246 | 1.00 | HRH4 (0.54) | HRH4PRKD1PRKD2KCNH2HRH3 | |
| SCHEMBL14693261 | 1.00 | HRH4 (0.54) | HRH4PRKD1PRKD2KCNH2HRH3 | |
| SCHEMBL13667218 | 0.91 | HRH4 (0.58) | HRH4KCNH2HRH3CXCR4 | |
| SCHEMBL14693270 | 0.91 | HRH4 (0.58) | HRH4KCNH2HRH3CXCR4 | |
| SCHEMBL14693243 | 0.88 | HRH4 (0.53) | HRH4PRKD1PRKD2HRH3CXCR4 | |
| SCHEMBL13667233 | 0.88 | HRH4 (0.53) | HRH4PRKD1PRKD2HRH3CXCR4 | |
| SCHEMBL16790181 | 0.88 | HRH4 (0.53) | HRH4PRKD1PRKD2HRH3CXCR4 | |
| SCHEMBL13667194 | 0.88 | HRH4 (0.53) | HRH4PRKD1PRKD2HRH3CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372849-B2 | Heterocyclic compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-02-12 | — | — | US | disclosed |
| US-20090264339-A1 | Heterocyclic Compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264339-A1 | Heterocyclic Compounds | AHR, NQO1, LTC4S | HRH4 818/4885PRKD1 4495/4885PRKD2 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.